A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. - Davis SL; Eckhardt SG; Diamond JR; Messersmith WA; Dasari A; Weekes CD; Lieu CH; Kane M; Choon Tan A; Pitts TM; Leong S (The oncologist, 2018)